FARMINGDALE, N.Y., March 16, 2011 /PRNewswire/ -- Misonix, Inc. (Nasdaq: MSON), a medical device company that designs, manufactures, and markets innovative, therapeutic, ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications, has announced a definitive agreement for non-exclusive distribution, with the exception of certain selected accounts, of the BoneScalpel Ultrasonic Bone Cutting System in the United States with Aesculap, Inc., which replaces a prior exclusive distribution agreement between the parties. The agreement is limited to clinical applications relative to the spine and cranium.
In response, Misonix will begin the marketing, sales, distribution and service of the BoneScalpel in the U.S., effective immediately, utilizing its 75 person surgical sales organization, which markets direct to hospitals and free-standing surgery centers. In addition to spine and cranial applications, the Misonix sales organization will market the product for a broad range of maxiofacial and other small bone clinical applications.
The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument while minimizing the peril associated with rotary sharps.
"Misonix is excited about adding BoneScalpel to our focused, domestic sales organization. With this Agreement, Misonix will now be selling the BoneScalpel worldwide," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Over time, we anticipate significant margin improvement and sales growth by allowing our proprietary sales organization the opportunity to sell another one of our key products under t